Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455475 | 0.84 | GAA (0.50) | GAAL3MBTL1NPC1RAB9ALMNA | |
| SCHEMBL457180 | 0.84 | GAA (0.57) | GAAL3MBTL1NPC1RAB9ALMNA | |
| Hydrochloric Acid SCHEMBL4747848 | 0.83 | GAA (0.56) | GAAL3MBTL1NPC1RAB9ALMNA | |
| SCHEMBL456542 | 0.81 | LMNA (0.46) | GAAL3MBTL1NPC1RAB9AADRA2A | |
| SCHEMBL454957 | 0.81 | PTPN11 (0.50) | GAANPC1RAB9ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4747208 | 0.80 | LMNA (0.45) | GAAL3MBTL1NPC1RAB9AADRA2A | |
| SCHEMBL2543132 | 0.78 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CRAD52TDP1 | |
| SCHEMBL455066 | 0.78 | PTPN11 (0.49) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL457343 | 0.78 | TP53 (0.52) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL454499 | 0.78 | PTPN11 (0.49) | GAANPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096151-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2013-04-18 | — | — | US | claimed |
| EP-2552440-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | claimed |
| WO-2008117079-A1 | ANTIMICROBIAL COMPOUNDS BASED UPON 4-AMINOQUINOLINE | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-10-02 | — | — | WO | claimed |
| EP-3228314-B1 | SULOCTIDIL FOR USE TO TREAT MICROBIAL INFECTIONS | HELPERBY THERAPEUTICS LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10265373-B2 | Pharmaceutical composition and method of treating a microbial infection with sulcotidil | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| WO-2018162928-A1 | METHOD FOR RESTORING EFFICACY OF AN ANTIBACTERIAL AGENT | HELPERBY THERAPEUTICS LIMITED (GB) | 2018-09-13 | — | — | WO | disclosed |
| US-9789101-B2 | Methods and compositions for treating microbial infection using pyrroloquinone | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3228314-A1 | VASODILATOR FOR USE TO TREAT MICROBIAL INFECTIONS | Helperby Therapeutics Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-9549965-B2 | Pharmaceutical composition for treating a microbial infection | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-01-24 | — | — | US | disclosed |
| US-20160082073-A1 | NOVEL USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2016-03-24 | — | — | US | disclosed |
| US-20130243886-A1 | NOVEL USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2013-09-19 | — | — | US | disclosed |
| EP-2613774-A2 | NOVEL USE | Helperby Therapeutics Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130096151-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2013-04-18 | — | — | US | disclosed |
| EP-2552440-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012032360-A2 | NOVEL USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096151-A1 | NOVEL COMBINATION AND USE | FPR2, LTA, FPR1 | GAA 1415/4885L3MBTL1 86/4885NPC1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.